What Manufacture You Deem of the FDA’s COVID-19 Selections?

In an start letter to Stephen Hahn, MD, the commissioner of the US Food and Drug Administration (FDA), Medscape Editor-in-Chief Eric Topol, MD, detailed why he thinks most stylish FDA authorizations of interventions to treat COVID-19 contain no longer been evidence-primarily primarily based. 

Topol cited three emergency spend authorizations (EUAs) that he says weren’t evidence-primarily primarily based: one for hydroxychloroquine on March 30 (revoked in June for lack of evidence), one for convalescent plasma on August 23, and an expanded EUA for remdesivir to treat any hospitalized COVID-19 patient, no longer appropriate these with excessive illness.  

Topol also cited a most stylish interview by which Hahn talked about he used to be willing to authorize a COVID-19 vaccine sooner than Section 3 trials were full.

“These repeated breaches portray your willingness to push aside the inability of scientific evidence, and to be complicit with the Trump Administration’s politicization of The US’s healthcare institutions,” Topol wrote.

Utter us what you seen about these choices.

Medscape Reader Polls © 2020 WebMD, LLC

Any views expressed above are the creator’s have and elevate out no longer essentially assume the views of WebMD or Medscape.

Cite this: What Manufacture You Deem of the FDA’s COVID-19 Selections? – Medscape – Sep 02, 2020.